Patents Assigned to Polaris Group
  • Combination cancer immunotherapies with arginine depletion agents
    Patent number: 12281339
    Abstract: Provided are arginine depletion agents such as ADI-PEG for use in combination with cancer immunotherapies, for example, immune checkpoint modulators and T-cell adoptive immunotherapies, for treating various cancers. Also provided are related methods, compositions, patient care kits, and cell cultures.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: April 22, 2025
    Assignee: POLARIS GROUP
    Inventors: Elena Brin, Wei He
  • Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment
    Patent number: 11235037
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 1, 2022
    Assignee: Polaris Group
    Inventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • Methods of treatment with arginine deiminase
    Patent number: 10525142
    Abstract: The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: Polaris Group
    Inventors: John S. Bomalaski, Bor-Wen Wu
  • Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment
    Patent number: 9789170
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 17, 2017
    Assignee: Polaris Group
    Inventors: Richard Showalter, Robert Almassy, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • Methods of treatment with arginine deiminase
    Patent number: 9731028
    Abstract: The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: August 15, 2017
    Assignee: Polaris Group
    Inventors: John S. Bomalaski, Bor-Wen Wu
  • Methods of treatment with arginine deiminase
    Patent number: 9333268
    Abstract: The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: May 10, 2016
    Assignee: Polaris Group
    Inventors: John S. Bomalaski, Bor-Wen Wu
  • ARGINNE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT
    Publication number: 20140348814
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 27, 2014
    Applicant: Polaris Group
    Inventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • Modified tumor necrosis factor
    Patent number: 7785579
    Abstract: Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not increasing its toxicity. As a result, lower doses of the TNF may be administered to effectively treat tumors with fewer, accompanying adverse side effects to the patient.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: August 31, 2010
    Assignee: Polaris Group
    Inventor: Mike A. Clark
  • PROTEIN KINASE INHIBITORS
    Publication number: 20090247501
    Abstract: Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds
    Type: Application
    Filed: March 3, 2009
    Publication date: October 1, 2009
    Applicant: Polaris Group
    Inventors: Shaosong Chu, Zhe Nie, Carin L. Perretta, Philip Eugene Erickson
  • Protein kinase inhibitors
    Patent number: 7517882
    Abstract: Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: April 14, 2009
    Assignee: Polaris Group
    Inventors: Shaosong Chu, Zhe Nie, Carin L. Perretta, Philip Eugene Erickson
  • Method of treatment with modified arginine deiminase
    Patent number: 7323167
    Abstract: The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: January 29, 2008
    Assignee: Polaris Group
    Inventor: Mike A. Clark